Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced that it will release its second quarter 2024 financial results on August 7, 2024. The company will also host a conference call on the same day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and recent corporate progress. Investors can access the call via a toll-free U.S. number or an international number, using the passcode 771307. Additionally, a webcast of the call will be available on Mirum's website in the Events & Presentations section, with a replay accessible for 30 days after the event.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre del 2024 il 7 agosto 2024. L'azienda terrà anche una conference call nello stesso giorno alle 16:30 ET / 13:30 PT per discutere i risultati finanziari e i recenti progressi aziendali. Gli investitori possono accedere alla chiamata tramite un numero verde statunitense o un numero internazionale, utilizzando il codice di accesso 771307. Inoltre, una registrazione della chiamata sarà disponibile sul sito web di Mirum nella sezione Eventi e Presentazioni, con una riproduzione accessibile per 30 giorni dopo l'evento.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024. La empresa también realizará una conferencia telefónica el mismo día a las 4:30 p.m. ET / 1:30 p.m. PT para discutir los resultados financieros y el progreso corporativo reciente. Los inversores pueden acceder a la llamada a través de un número gratuito en EE. UU. o un número internacional, utilizando el código de acceso 771307. Además, una transmisión en vivo de la llamada estará disponible en el sitio web de Mirum en la sección de Eventos y Presentaciones, con una repetición accesible durante 30 días después del evento.
미럼 제약(Mirum Pharmaceuticals, NASDAQ: MIRM)이 2024년 2분기 재무 결과를 2024년 8월 7일에 발표한다고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 전화를 통해 재무 결과와 최근의 기업 진행 상황에 대해 논의할 예정입니다. 투자자는 수신자 부담 미국 번호 또는 국제 번호를 통해 771307 비밀번호를 사용하여 전화를 이용할 수 있습니다. 또한, 미럼 웹사이트의 이벤트 및 발표 섹션에서 전화 통화의 웹캐스트를 제공하며, 이벤트 이후 30일 동안 다시 들을 수 있습니다.
Mirum Pharmaceuticals (NASDAQ: MIRM) a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre de 2024 le 7 août 2024. L'entreprise organisera également une conférence téléphonique le même jour à 16h30 ET / 13h30 PT pour discuter des résultats financiers et des progrès récents de l'entreprise. Les investisseurs peuvent accéder à l'appel via un numéro gratuit aux États-Unis ou un numéro international, en utilisant le code d'accès 771307. De plus, un webinaire de l'appel sera disponible sur le site Web de Mirum dans la section Événements et Présentations, avec une rediffusion accessible pendant 30 jours après l'événement.
Mirum Pharmaceuticals (NASDAQ: MIRM) hat bekannt gegeben, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 7. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT eine Konferenzschaltung durchführen, um die Finanzergebnisse und aktuelle Fortschritte im Unternehmen zu besprechen. Investoren können über eine kostenlose US-Nummer oder eine internationale Nummer auf den Anruf zugreifen und den Zugangscode 771307 verwenden. Darüber hinaus wird eine Webcast der Sitzung auf der Website von Mirum im Bereich Veranstaltungen & Präsentationen verfügbar sein, mit einer Rückschau, die 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
Conference call details:
Wednesday, August 7, 2024
4:30 p.m. ET / 1:30 p.m. PT
Dial-in:
International: +1 404 975 4839
Passcode: 771307
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731563929/en/
Investors:
Andrew McKibben
ir@mirumpharma.com
Media:
Erin Murphy
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
When will Mirum Pharmaceuticals (MIRM) report its Q2 2024 financial results?
What time is Mirum Pharmaceuticals' (MIRM) Q2 2024 earnings call scheduled for?
How can investors access Mirum Pharmaceuticals' (MIRM) Q2 2024 earnings call?
Will there be a replay available for Mirum Pharmaceuticals' (MIRM) Q2 2024 earnings call?
